Drug Approval | March 04, 2023
Caplin Steriles gets USFDA approval for Rocuronium Bromide Injection
Rocuronium Bromide Injection is a neuromuscular blocking agent
Rocuronium Bromide Injection is a neuromuscular blocking agent
Clinical studies are expected to start in Q2 2023.
Themis will market this drug with the brand name REMITHEM.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
It enables precise visualization and treatment access to the left heart
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
The drug is indicated for mild and transient episodes of heart block
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
